The Zhitong Finance App learned that Kingsley Biotech (01548) rose more than 7% in early trading. As of press release, it rose 5.69% to HK$42, with a turnover of HK$212 million.

According to the news, Kingsley recently announced that it has reached a cooperation with Lilly TuneLab, Eli Lilly's AIDD collaboration platform. The company will provide wet testing services to TuneLab participating companies to help them quickly generate experimental data, transform AI predictions into biological verification data, and accelerate the evaluation of drug candidates. Everbright Securities pointed out that the company's business model has profoundly changed as big model manufacturers lose the market for AI pharmaceuticals.

According to J.P. Morgan Chase's latest research report, Eli Lilly TuneLab chose King's Rui as one of the three core wet laboratory partners. The meaning is not just a single CRO order, but also a strategic entrance to enter the ecosystem of more than 100 Biotech customers and open up a closed loop of wet and dry experiments. Kingsley also has shares in Life Science Services, CDMO, BestZyMe, and about 45% of Legendary Biotech. Upgraded AIDD demand, capacity expansion, and late-stage business growth support.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.